All Releases
View Summary Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma
May 28, 2015
PDF 27.4 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
May 27, 2015
PDF 21.9 KB Add to Briefcase
View Summary Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting
May 13, 2015
PDF 26.8 KB Add to Briefcase
View Summary Celldex Reports First Quarter 2015 Results
Apr 29, 2015
PDF 38.0 KB Add to Briefcase
View Summary Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies
Apr 20, 2015
PDF 67.5 KB Add to Briefcase
View Summary Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology
Apr 6, 2015
PDF 28.7 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma
Apr 6, 2015
PDF 30.2 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A
Mar 17, 2015
PDF 30.9 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Upcoming Presentation at the Cowen and Company 35th Annual Health Care Conference
Mar 3, 2015
PDF 22.0 KB Add to Briefcase
View Summary Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares
Feb 27, 2015
PDF 25.2 KB Add to Briefcase
View Summary Celldex Therapeutics Prices Public Offering of Common Stock
Feb 25, 2015
PDF 25.4 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Proposed Public Offering of Common Stock
Feb 24, 2015
PDF 24.9 KB Add to Briefcase
View Summary Celldex Reports Fourth Quarter and Year-End 2014 Results
Feb 24, 2015
PDF 42.4 KB Add to Briefcase
View Summary Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma
Feb 23, 2015
PDF 26.7 KB Add to Briefcase
View Summary Celldex to Report Fourth Quarter and Fiscal 2014 Business/Financial Results and Host 2015 Corporate Strategy Conference Call
Feb 19, 2015
PDF 22.7 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Upcoming Presentation at the 2015 Leerink Global Healthcare Conference
Feb 9, 2015
PDF 22.1 KB Add to Briefcase
View Summary Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors
Jan 29, 2015
PDF 80.4 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Appointment to Board of Directors
Dec 18, 2014
PDF 25.4 KB Add to Briefcase
View Summary Celldex Announces Completion of Enrollment in Phase 3 Study of Rindopepimut in Frontline Glioblastoma
Dec 15, 2014
PDF 27.4 KB Add to Briefcase
View Summary Celldex Therapeutics Initiates a Phase 2 Study of Glembatumumab Vedotin in Patients with Advanced Melanoma
Dec 4, 2014
PDF 26.6 KB Add to Briefcase
Showing 41-60 of 142 Page: 1 2 3 4 5 6 7 8  Previous 20 | Next 20
Showing 41-60 of 142
Page: 1 2 3 4 5 6 7 8
 Previous 20 | Next 20
Add to Briefcase = add release to Briefcase